Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
Executive Summary
FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.
You may also be interested in...
Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program
Details from the COU-302 trial of Johnson & Johnson’s Zytiga, stopped early for efficacy in March, were released at the American Society of Clinical Oncology meeting, revealing to Medivation/Astellas insights on how to tweak their ongoing registrational trial for enzalutamide (MDV3100) in the pre-chemo prostate cancer space.
Eyeing Both A Partnership And An IPO, Aragon Takes $42M Series C
A well-connected fund that invests on behalf of a group of high-net-worth investors provides cash to complete a Phase II trial on prostate cancer drug ARN-509, and bring a breast cancer drug into the clinic.
Tokai Raises $23 Million In Series D Financing
The start up's focus is on a highly competitive indication, refractory prostate cancer, but its ability to raise money could be tied to the novelty of its lead compound